CALC – calcimedica, inc. (US:NASDAQ)
Stock Stats
News
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
CalciMedica, Inc. (NASDAQ: CALC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates [Yahoo! Finance]
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Form 10-K/A CalciMedica, Inc. For: Dec 31
Form 4 CalciMedica, Inc. For: Mar 28 Filed by: Guerard Frederic
Form 4 CalciMedica, Inc. For: Mar 28 Filed by: BJERKHOLT ERIC
Form 4 CalciMedica, Inc. For: Mar 28 Filed by: Shaw Allan
Form 4 CalciMedica, Inc. For: Mar 28 Filed by: MIDDLETON FRED A
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.